JP2022502498A5 - - Google Patents
Info
- Publication number
- JP2022502498A5 JP2022502498A5 JP2021540394A JP2021540394A JP2022502498A5 JP 2022502498 A5 JP2022502498 A5 JP 2022502498A5 JP 2021540394 A JP2021540394 A JP 2021540394A JP 2021540394 A JP2021540394 A JP 2021540394A JP 2022502498 A5 JP2022502498 A5 JP 2022502498A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- less
- days
- treatment cycle
- cytarabine
- Prior art date
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862736393P | 2018-09-25 | 2018-09-25 | |
| US62/736,393 | 2018-09-25 | ||
| US201862772372P | 2018-11-28 | 2018-11-28 | |
| US62/772,372 | 2018-11-28 | ||
| PCT/US2019/052952 WO2020068979A1 (en) | 2018-09-25 | 2019-09-25 | Low-intensity treatment of hematological disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022502498A JP2022502498A (ja) | 2022-01-11 |
| JPWO2020068979A5 JPWO2020068979A5 (https=) | 2022-09-30 |
| JP2022502498A5 true JP2022502498A5 (https=) | 2022-09-30 |
Family
ID=69950910
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021540394A Pending JP2022502498A (ja) | 2018-09-25 | 2019-09-25 | 血液疾患の低強度治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20240252522A1 (https=) |
| EP (1) | EP3856198A4 (https=) |
| JP (1) | JP2022502498A (https=) |
| KR (1) | KR20210065962A (https=) |
| CN (1) | CN113164502A (https=) |
| AU (1) | AU2019350759A1 (https=) |
| BR (1) | BR112021005539A2 (https=) |
| CA (1) | CA3114002A1 (https=) |
| IL (1) | IL281729A (https=) |
| MX (1) | MX2021003527A (https=) |
| WO (1) | WO2020068979A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108778260A (zh) * | 2015-11-11 | 2018-11-09 | 塞拉特药物股份有限公司 | 选择白血病对象的治疗方案的分析和方法 |
| EP3856198A4 (en) * | 2018-09-25 | 2022-06-22 | Celator Pharmaceuticals, Inc. | Low-intensity treatment of hematological disorders |
| US11980636B2 (en) | 2020-11-18 | 2024-05-14 | Jazz Pharmaceuticals Ireland Limited | Treatment of hematological disorders |
| EP4333822A1 (en) | 2021-05-03 | 2024-03-13 | Lead Discovery Center GmbH | Composition comprising an inhibitor of mitochondrial transcription |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7850990B2 (en) | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
| CA2462376C (en) | 2001-10-03 | 2010-12-14 | Celator Technologies Inc. | Liposome loading with metal ions |
| CA2467064C (en) | 2001-11-13 | 2011-02-08 | Murray Webb | Lipid carrier compositions with enhanced blood stability |
| WO2005102359A1 (en) | 2004-04-22 | 2005-11-03 | Celator Pharmaceuticals, Inc. | Liposomal formulations of anthracycline agents and cytidine analogs |
| EP4046640A1 (en) * | 2007-02-16 | 2022-08-24 | Rotalec IP Holdings LLC | Fixed drug ratios of cytarabine to daunorubicin for treatment of hematopoietic cancers and proliferative disorders |
| EP3572071A1 (en) | 2011-10-21 | 2019-11-27 | Jazz Pharmaceuticals Research LLC | Lyophilized liposomes |
| CN108778260A (zh) * | 2015-11-11 | 2018-11-09 | 塞拉特药物股份有限公司 | 选择白血病对象的治疗方案的分析和方法 |
| BR112019001570A2 (pt) * | 2016-07-28 | 2019-07-09 | Novartis Ag | terapias de combinação de receptores de antígeno quiméricos e inibidores de pd-1 |
| WO2018101214A1 (ja) | 2016-12-01 | 2018-06-07 | Ｊｘｔｇエネルギー株式会社 | 全芳香族液晶ポリエステル樹脂 |
| EP3856198A4 (en) * | 2018-09-25 | 2022-06-22 | Celator Pharmaceuticals, Inc. | Low-intensity treatment of hematological disorders |
| US11980636B2 (en) * | 2020-11-18 | 2024-05-14 | Jazz Pharmaceuticals Ireland Limited | Treatment of hematological disorders |
-
2019
- 2019-09-25 EP EP19864378.5A patent/EP3856198A4/en active Pending
- 2019-09-25 CN CN201980063289.2A patent/CN113164502A/zh not_active Withdrawn
- 2019-09-25 WO PCT/US2019/052952 patent/WO2020068979A1/en not_active Ceased
- 2019-09-25 BR BR112021005539-8A patent/BR112021005539A2/pt not_active Application Discontinuation
- 2019-09-25 AU AU2019350759A patent/AU2019350759A1/en not_active Abandoned
- 2019-09-25 MX MX2021003527A patent/MX2021003527A/es unknown
- 2019-09-25 JP JP2021540394A patent/JP2022502498A/ja active Pending
- 2019-09-25 US US17/279,556 patent/US20240252522A1/en not_active Abandoned
- 2019-09-25 CA CA3114002A patent/CA3114002A1/en active Pending
- 2019-09-25 KR KR1020217011132A patent/KR20210065962A/ko not_active Ceased
-
2021
- 2021-03-22 IL IL281729A patent/IL281729A/en unknown
- 2021-06-03 US US17/338,561 patent/US12370207B2/en active Active
-
2025
- 2025-06-24 US US19/247,599 patent/US20260014183A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022502498A5 (https=) | ||
| JP2023041862A5 (https=) | ||
| JP2021512149A5 (https=) | ||
| RU2010147287A (ru) | Комбинированная композиция | |
| JP2015513309A5 (https=) | ||
| JP3465824B2 (ja) | 腫瘍治療用医薬組成物 | |
| Oguchi et al. | Mucosa-adhesive water-soluble polymer film for treatment of acute radiation-induced oral mucositis | |
| KR20100052556A (ko) | 난청 치료 및 예방을 위한 1-아미노-알킬시클로헥산 유도체 | |
| JP2019515909A5 (https=) | ||
| WO2011159100A2 (ko) | 항암 활성을 나타내는 약제학적 조성물 | |
| Murty | Antiepileptic overdose | |
| JP2018138596A5 (https=) | ||
| JP2016505050A5 (https=) | ||
| JPWO2021045159A5 (https=) | ||
| CN107137417B (zh) | 一种用于治疗恶病质的药物组合物及其应用 | |
| JP2011500589A5 (https=) | ||
| JP2014534229A5 (https=) | ||
| JP2008517991A5 (https=) | ||
| RU2181588C2 (ru) | Способ профилактики отсроченной рвоты | |
| JPWO2020068979A5 (https=) | ||
| JP2009534367A5 (https=) | ||
| JPWO2022059692A5 (https=) | ||
| JPWO2022059691A5 (https=) | ||
| RU2021111401A (ru) | Низкоинтенсивная терапия гематологических нарушений | |
| JP2020526575A5 (https=) |